Psoriasis is a chronic disease which is characterized by extreme exfoliation of the skin which is cosmetically not good looking. Conventional treatment of Psoriasis includes application of gel based steroids and immune-suppressant drugs. However there is some good news for psoriasis patients, Novartis has announced that very good results have been obtained from its drug, secukinumab when used by patients suffering from moderate-to-severe plaque psoriasis.
Phase III study results were presented at the American Academy of Dermatology in Denver. The study results revealed that secukinumab was effective in treating psoriasis when administered with a pre-filled syringe or autoinjector pen. The above two methods allow the patients to administer the drug at home or in the workplace instead of going to any healthcare facility.
Tim Wright, global head of development for Novartis Pharmaceuticals said, “It is important that people living with psoriasis, a chronic skin disease, have highly effective and safe treatments they can conveniently self-administer,”
As mentioned Plaque Psoriasis is often painful and unpleasant skin condition. Psoriasis leads to intense itching. If the scabs gets infected by bacteria, it can lead to wet and oozing Psoriasis. If the psoriasis is infected by fungi, it can lead to itchy psoriasis.
The studies revealed that administration of secukinumab lead to improved prognosis which included clearing of the scabs after 12 weeks of treatment as compared to placebo. Patient compliance and satisfaction was also very high. Results of an earlier study last year showed the drug to be better than to Amgen’s Enbrel in a head-to-head study.
Secukinumab is also called AIN457 and Novartis has filed the drug for approval by health authorities in Europe and United States.